Richter Gedeon Nyrt.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
17
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Indole Derivatives (US 10,329,296) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Feb 18, 2027The maintenance fee for Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate (US 9,107,840) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 1 fee due May 26, 2027The maintenance fee for Immunoglobulin Purification Using Pre-Cleaning Steps (US 10,487,138) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,221,788 | Pharmaceutical compositions containing rosuvastatin calcium In force · From the USPTO record | In force | From the USPTO record | |
| US 8,481,527 | Benzamide derivatives as bradykinin antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 7,875,610 | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 7,943,621 | Salts of piperazine compounds as D3/D2 antagonists In force · From the USPTO record | In force | From the USPTO record | |
| US 8,450,476 | Process for the preparation of 17-hydroxy-6β,7β;15β,16β-bismethylene-17α-pregn-4-ene-3-one-21-carboxylic acid γ-lactone and key intermediates for this process In force · From the USPTO record | In force | From the USPTO record | |
| US 8,309,712 | Industrial process for the preparation of 17-hydroxy-6beta,7beta;15beta, 16beta-bismethylene-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid y-lactone and key intermediates for this process In force · From the USPTO record | In force | From the USPTO record | |
| US 8,765,765 | Metabolites of (thio) carbamoyl-cyclohexane derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US RE47,350 | Pharmaceutical formulations containing dopamine receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US RE49,302 | Pharmaceutical formulations containing dopamine receptor ligands In force · From the USPTO record | In force | From the USPTO record | |
| US 8,183,402 | Industrial method for the synthesis of 17-acetoxy-11β[4-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 44: 29 lapsed for an unpaid fee · 1 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 abandoned · 17 no status recorded